- Tim Cook Should Tell Congress to Kiss His Ass
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- 5 Worst Home Renovation Projects
- How the New York Hedge Funds Lost Their Shirts on Tesla
- What You Wear to the Office Still Matters

Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
07:00AM 05/10/13
Biotech's Next Big Thing: ASCO
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
09:39AM 05/09/13

Repros Patent Problems Began When Harry Met Joe
A New York fertility doctor accuses Repros CEO of stealing the idea for a new oral testosterone therapy.
08:00AM 05/09/13

Amarin Trouble Grows As Does Evidence Against Fish Oil's Benefits
Fish oil supplements have no heart benefits for patients, which doesn't bode well for Amarin's efforts to market Vascepa.
12:15AM 05/09/13

Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Used
Osiris CEO claims Prochymal is most widely used stem cell drug in world yet has generated no sales -- ever.
01:19PM 05/07/13

Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives
DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.
11:53AM 05/07/13

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal
Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.
12:26PM 05/06/13

Leaders of TheStreet's Drug Approval Contest
This group of contestants have nearly perfect records picking FDA and European drug approvals.
09:21AM 05/06/13

Aveo, Delcath FDA Panel Live Blog
Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems
07:44AM 05/02/13

An Outrageous, Shameless Act by Hemispherx's Board of Directors
Hemispherx CEO earns a bonus for overseeing the sale of company stock.
12:03PM 05/01/13
RSS Feed